Discover trends, market shifts, and competitive outlooks for the non-invasive prenatal testing industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Non-invasive Prenatal Testing Market Size from 2025 to 2034?

The market size of non-invasive prenatal testing has experienced swift expansion in the past few years. The market is projected to escalate from $5.48 billion in 2024 to $6.28 billion in 2025, with a compound annual growth rate (CAGR) of 14.7%. Factors such as enhanced precision, diminished risk, rise in maternal age, augmented awareness, and clinical guidelines have contributed to the growth during the historic period.

The market for non-invasive prenatal testing is predicted to experience a swift expansion in the coming years, reaching a value of $10.95 billion in 2029, progressing at a compound annual growth rate (CAGR) of 14.9%. The growth anticipated in this period can be linked to factors such as broadening test options, more widespread availability, increasing maternal age, detection of fetal anomalies, and the rise of telemedicine as well as digital health. Key trends projected during this forecast period involve the enlargement of test panels, increased adoption of nipt, advancements in technology, and non-invasive fetal aneuploidy diagnosis (nifad).

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2492&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Non-invasive Prenatal Testing Market?

The rising occurrence of Down syndrome is a significant force propelling the growth of the non-invasive prenatal testing market. This is largely due to the increase in the average maternal age which raises concerns about the wellbeing and development of the fetus. Down syndrome is a chromosomal anomaly that happens due to an error in cell division, leading to an extra 21st chromosome. This extra chromosome can impact the cognitive and physical growth of the fetus. Non-invasive prenatal testing (NIPT) poses no harm to both the mother and baby, and carries no miscarriage risk as it is non-invasive. In addition, it can identify over 99% of Down syndrome cases. As per the National Down Syndrome Society and the Centres for Disease Control and Prevention, 1 in every 700 babies born in the United States has Down syndrome and 80% of such children are born to older mothers. This elevated risk of older mothers having babies with Down syndrome fuels the expansion of the non-invasive prenatal testing market.

Which Key Market Segments Comprise the Non-invasive Prenatal Testing Market and Drive Its Revenue Growth?

The non-invasive prenatal testing market covered in this report is segmented –

1) By Type: Consumables, Instruments

2) By Application: Trisomy, Microdeletion, Genetics, Rh factor

3) By End User: Hospital, Diagnostic Labs

Subsegment:

1) By Consumables: Assay Kits, Reagents, Disposables

2) By Instruments: Next-Generation Sequencers (NGS), Polymerase Chain Reaction (PCR) Systems, Ultrasound Devices, Others (Microarrays And Mass Spectrometers)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2492&type=smp

Which Areas Are Leading Regions in the Non-invasive Prenatal Testing Market Expansion Across the Globe?

North America was the largest region in the non-invasive prenatal testing market in 2023. Western Europe was the second largest region in the non-invasive prenatal testing market. The regions covered in the non-invasive prenatal testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Cutting-Edge Market Trends Are Expected to Drive the Non-invasive Prenatal Testing Market’s Growth?

The advancement in next-generation sequencing technology has boosted throughput, scalability, and speed, allowing for a broader range of applications and deeper studies into biological systems. Next-generation sequencing platforms permit simultaneous sequencing of thousands to millions of DNA molecules. This technology, which has been introduced by manufacturers to save time and money, enhances the output for genome and DNA testing results. Leading corporations like Illumina, Eurofins, Natera, Roche, and Annoroad have harnessed this technology for non-invasive prenatal testing. The China Food and Drug Administration (CFDA) has given its approval for the application of the NGS instrument NextSeq 550AR produced by Annoroad in the product registration of medical instruments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/non-invasive-prenatal-testing-global-market-report

How Is the Non-invasive Prenatal Testing Market Conceptually Defined?

Non-invasive prenatal testing is a test in which blood from the mother is drawn and tested for possible abnormalities in the patient. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, mainly chromosome defects, in fetuses in the first trimester of pregnancy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2492

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.